Compounds > clopidogrel

clopidogrel and Obesity

clopidogrel has been researched along with Obesity in 27 studies

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (14.81)29.6817
2010's15 (55.56)24.3611
2020's8 (29.63)2.80

Authors

AuthorsStudies
Donia, HM; El-Askary, NA; El-Behery, AM; El-Khodary, NM; Omran, GA1
Friebel, J; Hassanein, A; Jakobs, K; Landmesser, U; Puccini, M; Rauch, C; Rauch, U1
Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X1
Chen, Z; Mo, J; Wang, Y1
Schlemm, E; Schlemm, L1
Angiolillo, DJ; Bergmeijer, TO; Capodanno, D; Danchin, N; Price, MJ; Sibbing, D; Simon, T; Ten Berg, JM1
Kreutz, RP1
Ge, PX; Ji, JZ; Jiang, LP; Li, YF; Mi, QY; Tai, T; Xie, HG; Zhu, T1
Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M1
Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V1
Daels, FP; de la Rosette, JJ; Erkan, E; Gaizauskas, A; Melekos, M; Ozgok, Y; Rioja, J; Varshney, AK1
Kioufis, S; Kokkou, E; Mourouzis, K; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stone, PH; Tousoulis, D; Vavuranakis, M; Vlasis, K; Zaromitidou, M1
Bain, JA; Beavers, CJ; Heron, P; Macaulay, TE; Smyth, SS1
Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K1
Barbato, E; Chenu, P; Legrand, D; Legrand, V; Magne, J; Vrolix, M; Wijns, W1
Horenstein, RB; Jiang, XL; Lesko, LJ; Lewis, JP; Peletier, LA; Samant, S; Schmidt, S; Shuldiner, AR1
Karadağ, B1
Çiftçi, C; Doğan, A; Görmüş, U; Kahraman, S; Özdemir, E; Usta, E1
Monte, SV; Norgard, NB1
Cheng, WJ; Ge, HL; Guo, YH; Jia, DA; Liu, YY; Nie, B; Shi, DM; Wang, ZJ; Yan, ZX; Yang, SW; Yu, M; Zhao, YX; Zhou, YJ1
Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C1
Dellon, ES; Scholl, S; Shaheen, NJ1
Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S1
Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z1
Patel, MR; Peterson, ED1
Schaerlig, E1
Boden, WE; Diercks, DB; Gibler, WB; Kirk, JD; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC1

Reviews

2 review(s) available for clopidogrel and Obesity

ArticleYear
Obesity and Antiplatelets-Does One Size Fit All?
    Thrombosis research, 2015, Volume: 136, Issue:4

    Topics: Clopidogrel; Drug Therapy, Combination; Humans; Obesity; Platelet Aggregation Inhibitors; Ticlopidine

2015
Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics.
    Drug metabolism letters, 2017, 11-17, Volume: 11, Issue:1

    Topics: Cardiovascular Diseases; Clopidogrel; Humans; Inflammation; Obesity; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine

2017

Trials

5 trial(s) available for clopidogrel and Obesity

ArticleYear
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2023, 07-10, Volume: 195, Issue:26

    Topics: Aspirin; Body Mass Index; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Obesity; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome

2023
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:2

    Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2014
The STIB score: a simple clinical test to predict clopidogrel resistance.
    Acta cardiologica, 2015, Volume: 70, Issue:5

    Topics: Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Belgium; Biomarkers; Blood Platelets; Body Mass Index; Chi-Square Distribution; Clopidogrel; Comorbidity; Decision Support Techniques; Diabetes Complications; Drug Resistance; Female; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Obesity; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Testing; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome

2015
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Basic research in cardiology, 2010, Volume: 105, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Humans; Leukocytes; Male; Obesity; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Ticlopidine

2010
Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
    Angiology, 2013, Volume: 64, Issue:7

    Topics: Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obesity; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Implantation; Stents; Tetrazoles; Thrombosis; Ticlopidine; Treatment Outcome

2013

Other Studies

20 other study(ies) available for clopidogrel and Obesity

ArticleYear
The correlation between platelet responsiveness to clopidogrel and CYP2C19 polymorphism in patients with peripheral vascular disease.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:19

    Topics: Aged; Alleles; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Drug Resistance; Egypt; Female; Genotype; Humans; Male; Middle Aged; Obesity; Peripheral Vascular Diseases; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide

2021
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
    Cardiovascular drugs and therapy, 2023, Volume: 37, Issue:4

    Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine

2023
Response by Chen et al to Letter Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".
    Stroke, 2020, Volume: 51, Issue:3

    Topics: Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Obesity; Overweight; Stroke

2020
Letter by L. Schlemm and E. Schlemm Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".
    Stroke, 2020, Volume: 51, Issue:3

    Topics: Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Obesity; Overweight; Stroke

2020
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
    JACC. Cardiovascular interventions, 2020, 03-09, Volume: 13, Issue:5

    Topics: Age Factors; Aged; Body Mass Index; Clinical Decision Rules; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Databases, Factual; Diabetes Mellitus; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Obesity; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Reproducibility of Results; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome

2020
IL-1R (Interleukin-1 Receptor) Signaling and Attenuated Hepatic CYP (Cytochrome P450) 2C Expression: Explanation for Higher Rate of Clopidogrel Resistance in Patients With Diabetes Mellitus?
    Arteriosclerosis, thrombosis, and vascular biology, 2020, Volume: 40, Issue:6

    Topics: Animals; Clopidogrel; Cytochrome P-450 Enzyme System; Diabetes Mellitus; Diet; Disease Models, Animal; Humans; Mice; Obesity; Receptors, Interleukin-1

2020
Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice.
    British journal of pharmacology, 2022, Volume: 179, Issue:1

    Topics: Animals; Blood Platelets; Clopidogrel; Humans; Mice; Obesity; Overweight; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine

2022
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
    The American journal of cardiology, 2014, Jan-01, Volume: 113, Issue:1

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Obesity; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thiophenes; Ticlopidine; United States

2014
Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study.
    World journal of urology, 2015, Volume: 33, Issue:6

    Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Comorbidity; Coumarins; Diabetes Mellitus; Female; Humans; Hypertension; Kidney Calculi; Male; Middle Aged; Obesity; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Prevalence; Prospective Studies; Risk Factors; Ticlopidine; Treatment Outcome; Ureteral Calculi; Ureteroscopy; Urolithiasis; Young Adult

2015
Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Atherosclerosis, 2015, Volume: 242, Issue:1

    Topics: Activation, Metabolic; Aged; Aspirin; Brachial Artery; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Female; Genotype; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Stents; Thrombophilia; Ticlopidine; Vasodilation

2015
Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention.
    Polskie Archiwum Medycyny Wewnetrznej, 2015, Volume: 125, Issue:9

    Topics: Aged; Angina, Stable; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Obesity; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine

2015
Identifying clinically relevant sources of variability: The clopidogrel challenge.
    Clinical pharmacology and therapeutics, 2017, Volume: 101, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Body Mass Index; Clopidogrel; Computer Simulation; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Interactions; Female; Gastrointestinal Absorption; Half-Life; Humans; Liver; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Obesity; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Socioeconomic Factors; Ticlopidine

2017
Obesity, leptin, and thrombosis: Focus on clopidogrel resistance.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2016, Volume: 44, Issue:7

    Topics: Animals; Biomedical Research; Clopidogrel; Drug Resistance; Humans; Leptin; Mice; Obesity; Thrombosis; Ticlopidine

2016
Effect of obesity and serum leptin level on clopidogrel resistance.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2016, Volume: 44, Issue:7

    Topics: Aged; Clopidogrel; Cohort Studies; Drug Resistance; Female; Humans; Leptin; Male; Middle Aged; Obesity; Ticlopidine

2016
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:19

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coronary Disease; Death, Sudden, Cardiac; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Obesity; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombosis; Ticlopidine

2009
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:3

    Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esophagus; Clopidogrel; Drug Interactions; Drug Prescriptions; Esophageal Neoplasms; Esophagitis; Esophagoscopy; Gastroesophageal Reflux; Gastroscopy; Heartburn; Hip Fractures; Humans; Intestinal Absorption; Middle Aged; Obesity; Odds Ratio; Platelet Aggregation Inhibitors; Population Surveillance; Prevalence; Proton Pump Inhibitors; Ticlopidine; Vitamin B 12

2011
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
    Translational research : the journal of laboratory and clinical medicine, 2013, Volume: 161, Issue:5

    Topics: Adenosine Diphosphate; Aged; Angioplasty; Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; P-Selectin; Phosphoproteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptor, PAR-1; Stents; Thrombosis; Ticlopidine; Translational Research, Biomedical

2013
Clopidogrel dosing in overweight patients: does one size fit all?
    The Journal of invasive cardiology, 2004, Volume: 16, Issue:4

    Topics: Blood Vessel Prosthesis Implantation; Body Mass Index; Body Weight; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Humans; Obesity; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine

2004
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
    Revue medicale suisse, 2005, May-04, Volume: 1, Issue:18

    Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesity; Piperidines; Platelet Aggregation Inhibitors; Pyrazoles; Rimonabant; Stroke; Ticlopidine

2005
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A
    American heart journal, 2006, Volume: 152, Issue:1

    Topics: Aged; Angina, Unstable; Body Mass Index; Clopidogrel; Female; Guideline Adherence; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Obesity; Odds Ratio; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Quality of Health Care; Risk Assessment; Risk Factors; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome; United States

2006